Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly vs Triweekly Fosaprepitant for Nausea Prevention in NPC
NCT04636632Phase 1Completed
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Complete Response at 7 weeks. Started Nov 2020; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT04636632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636632.